Section 4 of 6
Clinical evidence
121 evidence topics · 22 sources
Study summaries
Himalayas-1
Objective
Primary objective: radiographic progression-free survival superiority
Location and study date
Registry status and dates
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |
| First posted | “2026-07-23” |
Anticipated primary endpoint readout relative to cash runway
Study design
Randomized phase 3 design with physician's choice of control
| Study characteristic | Quoted record |
|---|---|
| Design | “Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Protocol number | “ORIC-944-05” |
| EU trial number | “2026-525340-15-00” |
Randomization and stratification
Protocol finalized after end-of-phase 1 interactions with regulators
Sponsorship and darolutamide supply agreement
Eligibility criteria
Excluded and permitted prior therapies in the registry record
Treatment
Investigational and control regimens
| Study drug and arm | Quoted dose and schedule |
|---|---|
| Rinzimetostat (investigational arm) | “400 mg once daily (QD)” |
| Darolutamide (investigational arm and physician's choice) | “600 mg twice daily (BID)” |
| Enzalutamide (physician's choice) | “160 mg once daily (QD)” |
| Docetaxel (physician's choice) | “75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles” |
Basis for the rinzimetostat dose
Study outcomes
Rationale for using radiographic progression-free survival by blinded independent central review as the primary endpoint
Trial definition of radiographic progression-free survival
Key secondary endpoint: overall survival
Other secondary efficacy, safety, and pharmacokinetic endpoints
Patient-reported outcome endpoints
Consensus definition of radiographic progression-free survival
“Radiographic progression-free survival (rPFS) is the time interval from random assignment to the date when the first site of disease is found to progress (using a manifestation-specific definition of progression), or death, whichever occurs first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of particular note is the use of the 2+2 rule to distinguish flare from true progression in patients with osseous disease at baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus position on the association with overall survival
“The association between rPFS and overall survival is still being investigated, but an association was demonstrated in at least one of these trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The suitability of efficacy end points to demonstrate clinical benefit is context dependent, and consultation with regulatory authorities is strongly recommended when selecting and defining end points for a trial intended to support drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with abiraterone
“Spearman's correlation coefficient between rPFS and OS was 0.72.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data make no surrogate claims of rPFS and do not provide support for the use of rPFS to serve as a substitute for OS at this juncture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with enzalutamide
“Spearman ρ was 0.72 (95% CI, 0.67-0.76) among all patients, 0.89 (95% CI, 0.86-0.92) among enzalutamide-treated patients, and 0.53 (95% CI, 0.43-0.61) among placebo-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our analysis, the lower correlation between rPFS and OS seen with placebo-treated patients than seen with enzalutamide-treated patients could be partly related to postprotocol exposure to life-prolonging therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival after prior androgen receptor pathway inhibitor and taxane
“In the overall population, rPFS correlated strongly with OS (rho ≥ 0.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Correlations between rPFS or OS and time to SSE without death were weak or mild.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial-level surrogacy in first-line mCRPC naive to androgen receptor pathway inhibitors
“Eleven RCTs were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using the methodology recommended by the German health authority IQWiG, this study supports rPFS as a valid intermediate endpoint for OS in first-line ARPi naïve mCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial-level surrogacy across advanced prostate cancer
“A total of 143 randomized trials (n=75,601 patients) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“radiographic PFS [n=52,548], 0.50 [95% CI, 0.35 to 0.63]” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical progression without radiographic progression
“Of 736 patients with disease progression, 280 (38%) had UCP-only and 124 (17%) had UCP plus RAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Including UCP events lowered estimates of treatment benefit—median crPFS was 13.3 months (95% CI 11.1 to 13.8) versus median rPFS of 16.5 months (95% CI 13.8 to 16.8) in AAP group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment by sites and countries
Description of analysis sets
Planned primary analysis of radiographic progression-free survival
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: design and data limitations
- No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
- The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
- The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
- Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
- Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
- The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.
Open-label design
Prespecified physician's choice of control
ORIC-944-01
Objective
Study purpose: single agent and combination with androgen receptor pathway inhibitors
Combination dose optimization: objective of selecting the recommended phase 3 dose
Food-effect cohort: objective
Location and study date
Registry dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2022-06-01” |
| Primary completion (estimated) | “2027-06” |
| Study completion (estimated) | “2028-04” |
Study sites in the United States, Australia, Spain, and the United Kingdom
“Memorial Sloane Kettering Cancer Center” (opens the source at this quote in a new tab)
“Huntsman Cancer Institute, University of Utah” (opens the source at this quote in a new tab)
“Sydney Adventist Health” (opens the source at this quote in a new tab)
“Vall d'Hebron Institute of Oncology” (opens the source at this quote in a new tab)
“Royal Marsden NHS Foundation Trust” (opens the source at this quote in a new tab)
Investigational new drug application and start of combination dosing
Clinical supply collaborations for the combination cohorts
Completion of dose exploration in November 2025
Study design
First-in-human, open-label, multicenter, three-part design
Combination dose optimization cohorts by partner androgen receptor inhibitor
Combination dose exploration: November 2025 update
Combination dose optimization: March 2026 update
Post-androgen receptor inhibitor and food-effect cohorts
Eligibility criteria
Inclusion criteria: disease and castration status
Inclusion criteria: prior therapy by study part
Inclusion criteria: progression, measurable disease, biopsies, and performance status
Exclusion criteria
Combination cohorts: key eligibility as presented by the company
Treatment
Registry interventions and regimens
| Intervention | Quoted regimen |
|---|---|
| ORIC-944 | “Oral, once daily, continuous” |
| Apalutamide | “Oral, 240 mg once daily, continuous” |
| Darolutamide | “Oral, 600 mg twice daily, continuous” |
| Abiraterone acetate | “Oral, 1000 mg once daily, continuous” |
| Enzalutamide | “Oral, 160 mg once daily, continuous” |
Single-agent dose escalation: dose levels at the December 2024 cutoff
Apalutamide combination dose escalation: first two cohorts at the December 2024 cutoff
Combination dose exploration: dose levels at the May 2025 cutoff
Combination dose exploration: dose levels at the September 2025 cutoff and provisional doses for dose optimization
Darolutamide dose optimization, 400 mg and 600 mg: regimens at the January 2026 cutoff
Post-androgen receptor inhibitor cohort: regimen at the March 2026 cutoff
Study outcomes
Rationale for using recommended phase 2 dose as the primary endpoint
Combination dose optimization: primary, secondary, and exploratory endpoints at the March 2026 update
Single-agent dose escalation: tolerability beyond the projected efficacious dose
Combination dose exploration: basis for the provisional recommended phase 2 doses
Darolutamide dose optimization: recommended phase 3 dose selected by exposure-response analysis under Project Optimus
Exposure-response analysis: objective, methods, and correlations at the January 2026 cutoff
| Measure | Statistically significant correlation to exposure |
|---|---|
| Adverse events (G2+, G3+, SAEs) | “Significant correlation” |
| Specific adverse events (GI, heme) | “Significant correlation” |
| Treatment modifications | “Significant correlation” |
| Radiographic PFS | “No correlation” |
| PSA reduction | “No correlation” |
| ctDNA reduction | “No correlation” |
| Changes in H3K27me3 trimethylation | “No correlation” |
PSA50 and PSA90 response: confirmation
Circulating tumor DNA response and clearance: definitions
Circulating tumor DNA: stated prognostic rationale
Landmark radiographic progression-free survival: stated rationale
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “275” |
Single-agent dose escalation: participants at the December 2024 cutoff
Combination dose exploration: participants at the May 2025 cutoff
Combination dose exploration: participants at the September 2025 cutoff
Darolutamide dose optimization: participants analyzed at the January and March 2026 cutoffs
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set: participants at the January 2026 cutoff
Food-effect cohort: participants at the March 2026 cutoff
Description of analysis sets
Single-agent and apalutamide combination cohorts: adverse event attribution
Combination dose exploration: PSA, circulating tumor DNA, and safety sets at the September 2025 cutoff
Darolutamide dose optimization, 400 mg: PSA and circulating tumor DNA sets at the March 2026 update
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set: composition
Results
Participant disposition
Apalutamide combination dose escalation: disposition at the December 2024 cutoff
Combination dose exploration: treatment status at the May 2025 cutoff
Combination dose exploration: dose holds and discontinuation at the September 2025 cutoff
Darolutamide dose optimization, 400 mg: treatment status and discontinuation at the January and March 2026 cutoffs
Baseline characteristics
Combination dose exploration: demographics and baseline characteristics at the September 2025 cutoff
| Characteristic | Rinzimetostat plus apalutamide or darolutamide (N=20) |
|---|---|
| Age, median (range), years | “71 (48-85)” |
| Race, White / Black or African American / Asian, % | “70 / 25 / 5” |
| ECOG performance status 0 / 1, n (%) | “12 (60) / 8 (40)” |
| Gleason score <8 / ≥8, n (%) | “4 (20) / 15 (75)” |
| Prior lines of therapy, median (range) | “3 (2-5)” |
| Prior abiraterone, n (%) | “20 (100)” |
| Prior docetaxel, n (%) | “7 (35)” |
| Prior immune therapy, n (%) | “7 (35)” |
| Prior PARP inhibitor, n (%) | “2 (10)” |
| Prior radium 223, n (%) | “2 (10)” |
| Prior other therapy, n (%) | “6 (30)” |
| Bone metastases, n (%) | “17 (85)” |
| Lymph node metastases, n (%) | “8 (40)” |
| Visceral metastases, n (%) | “3 (15)” |
Darolutamide dose optimization, 400 mg and 600 mg post-abiraterone cohorts: demographics and baseline characteristics at the January 2026 cutoff
| Characteristic | Rinzimetostat 400 mg QD plus darolutamide (n=18) | Rinzimetostat 600 mg QD plus darolutamide (n=15) |
|---|---|---|
| Age, median (range), years | “67 (51, 85)” | “77 (58, 91)” |
| Race, White / Black / Asian, % | “56 / 33 / 6” | “67 / 27 / 0” |
| ECOG performance status 0 / 1, % | “56 / 44” | “53 / 47” |
| Gleason score <8 / ≥8 / unknown, % | “6 / 67 / 28” | “33 / 40 / 27” |
| Baseline PSA, median, ng/mL | “26” | “12” |
| Prior lines of therapy, median (range) | “2 (1-4)” | “2 (1-4)” |
| Prior abiraterone, n (%) | “18 (100)” | “15 (100)” |
| Prior docetaxel, n (%) | “7 (39)” | “2 (13)” |
| Prior immune therapy, n (%) | “3 (17)” | “2 (13)” |
| Prior PARP inhibitor, n (%) | “1 (6)” | “3 (20)” |
| Prior radium 223, n (%) | “3 (17)” | “0” |
| Prior other therapy, n (%) | “1 (6)” | “0” |
| Bone metastases, n (%) | “15 (83)” | “12 (80)” |
| Lymph node metastases, n (%) | “9 (50)” | “4 (27)” |
| Lung metastases, n (%) | “1 (6)” | “3 (20)” |
Efficacy results
Single-agent dose escalation: pharmacokinetics and target engagement at the December 2023 cutoff
Apalutamide combination dose escalation, 600 mg and 800 mg: PSA response at the December 2024 cutoff
Combination dose exploration, 400 mg to 800 mg: PSA response at the May 2025 cutoff
Combination dose exploration, 400 mg to 1,200 mg: PSA response at the September 2025 cutoff
| Response | Unconfirmed | Confirmed |
|---|---|---|
| PSA50 | “11/20 (55%)” | “8/20 (40%)” |
| PSA90 | “4/20 (20%)” | “4/20 (20%)” |
Combination dose exploration, 400 mg to 1,200 mg: circulating tumor DNA response and clearance at the September 2025 cutoff
| ctDNA status, baseline to on-treatment | Quoted value |
|---|---|
| Detected to not detected | “59% (10/17)” |
| Detected to detected | “29% (5/17)” |
| Not detected to not detected | “12% (2/17)” |
| Not detected to detected | “0% (0/17)” |
Darolutamide dose optimization, 400 mg: landmark radiographic progression-free survival at the March 2026 cutoff
| Landmark | Radiographic progression-free survival (median follow-up 4.9 months) |
|---|---|
| Month 3 | “3-Month 93%” |
| Month 4 | “4-Month 84%” |
| Month 5 | “5-Month 84%” |
Darolutamide dose optimization, 400 mg: PSA response at the January and March 2026 cutoffs
| Response | Unconfirmed | Confirmed |
|---|---|---|
| PSA50 | “7/15 (47%)” | “5/15 (33%)” |
| PSA90 | “2/15 (13%)” | “1/15 (7%)” |
Darolutamide dose optimization, 400 mg: circulating tumor DNA molecular response at the March 2026 cutoff
| Response | Quoted value |
|---|---|
| MR50 | “10/14 (71%)” |
| MR90 | “4/14 (29%)” |
Darolutamide dose optimization, 600 mg: efficacy relative to 400 mg in the exposure-response analysis at the January 2026 cutoff
Single-agent and darolutamide combination cohorts: pharmacokinetics and target engagement at the March 2026 update
Post-androgen receptor inhibitor cohort, 400 mg: landmark radiographic progression-free survival at the March 2026 cutoff
Food-effect cohort, 400 mg fed: pharmacokinetics and PSA response at the March 2026 cutoff
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Single-agent dose escalation: safety at the December 2023 cutoff
Single-agent dose escalation: treatment-related adverse events in at least 10% of participants at the December 2024 cutoff
| Preferred term | 900 mg (N=6), all grade, n (%) | 900 mg (N=6), grade 3, n (%) | Total (N=25), all grade, n (%) | Total (N=25), grade 3, n (%) |
|---|---|---|---|---|
| Diarrhea | “2 (33)” | “–” | “10 (40)” | “–” |
| Fatigue | “3 (50)” | “–” | “8 (32)” | “–” |
| Decreased appetite | “1 (17)” | “–” | “8 (32)” | “–” |
| Nausea | “3 (50)” | “–” | “7 (28)” | “–” |
| Anemia | “2 (33)” | “2 (33)” | “5 (20)” | “3 (12)” |
| Platelet count decreased | “3 (50)” | “2 (33)” | “5 (20)” | “2 (8)” |
| White blood cell count decreased | “2 (33)” | “1 (17)” | “3 (12)” | “1 (4)” |
| Blood creatinine increased | “1 (17)” | “–” | “3 (12)” | “–” |
| Dizziness | “1 (17)” | “–” | “3 (12)” | “–” |
| Vomiting | “1 (17)” | “–” | “3 (12)” | “–” |
Apalutamide combination dose escalation, 600 mg and 800 mg: safety at the December 2024 cutoff
Combination dose exploration, 400 mg to 800 mg: safety at the April 2025 cutoff
Combination dose exploration, 400 mg to 1,200 mg: treatment-emergent adverse events attributed to study treatment at the September 2025 cutoff
| Preferred term | 400 mg (n=3), grade 1-2 | 400 mg, grade 3 | 600 mg (n=9), grade 1-2 | 600 mg, grade 3 | 800 mg (n=5), grade 1-2 | 800 mg, grade 3 | 1,200 mg (n=3), grade 1-2 | 1,200 mg, grade 3 | Total (N=20), grade 1-2 | Total, grade 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | “1 (33%)” | “–” | “3 (33%)” | “1 (11%)” | “4 (80%)” | “–” | “3 (100%)” | “–” | “11 (55%)” | “1 (5%)” |
| Fatigue | “1 (33%)” | “–” | “4 (44%)” | “–” | “3 (60%)” | “–” | “1 (33%)” | “–” | “9 (45%)” | “–” |
| Nausea | “1 (33%)” | “–” | “3 (33%)” | “–” | “2 (40%)” | “–” | “1 (33%)” | “–” | “7 (35%)” | “–” |
| Dysgeusia | “1 (33%)” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “5 (25%)” | “–” |
| Vomiting | “–” | “–” | “3 (33%)” | “–” | “1 (20%)” | “–” | “–” | “–” | “4 (20%)” | “–” |
| Hypothyroidism | “–” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “4 (20%)” | “–” |
| Constipation | “–” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “–” | “–” | “3 (15%)” | “–” |
| Blood creatinine increased | “1 (33%)” | “–” | “–” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “3 (15%)” | “–” |
Darolutamide dose optimization, 400 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 600 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 400 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 600 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | All grade, n (%) |
|---|---|---|---|---|
| Fatigue | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Diarrhea | “8 (23)” | “5 (14)” | “–” | “13 (37)” |
| Nausea | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Blood creatinine increased | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Decreased appetite | “4 (11)” | “1 (3)” | “–” | “5 (14)” |
| Anemia | “2 (6)” | “3 (9)” | “1 (3)” | “6 (17)” |
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): grade 4 events at the January 2026 cutoff
Darolutamide dose optimization, post-abiraterone cohorts (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff
Food-effect cohort, 400 mg fed: safety at the March 2026 cutoff
Study limitations
Summary: design and data limitations
- ORIC-944-01 is a first-in-human, open-label, multicenter phase 1/1b study with an interval 3+3 dose escalation design. Every cohort received rinzimetostat, alone or with an ARPI, and the study has no control arm. The primary endpoints of combination dose optimization are safety and the RP3D; rPFS, objective response rate, and duration of response are key secondary endpoints, and PSA and ctDNA are exploratory endpoints. The registry lists an estimated enrollment of 275 and an estimated primary completion in 2027-06.
- Cohorts are small: 25 participants in single-agent dose escalation, 6 in the first apalutamide combination cohorts, 17 and then 20 in combination dose exploration, 18 at 400 mg and 15 at 600 mg in the post-abiraterone darolutamide dose-optimization cohorts, 19 in the post-androgen receptor inhibitor cohort, and 5 in the first food-effect report. The dose-exploration results pool participants who received apalutamide or darolutamide at 400 mg to 1,200 mg, and a footnote excludes three participants previously treated with lutetium 177, one of whom achieved a PSA50 response.
- Follow-up is short: a median of 4.9 months in the 400 mg post-abiraterone cohort and 4.8 months in the post-androgen receptor inhibitor cohort. rPFS is reported as landmark rates; ORIC states that “Radiographic Progression-Free Survival Data Are Immature” and lists median rPFS as “Not mature”.
- Endpoints of the 400 mg cohort come from different cutoffs and subsets: rPFS as of March 6, 2026 in 18 participants; PSA response at the January 16, 2026 clinical cutoff in 15 participants, excluding three without post-baseline PSA assessments; and ctDNA response in 14 participants (data on file as of March 11, 2026), excluding one without ctDNA at baseline and three without ctDNA data. Unconfirmed PSA responses are reported together with confirmed responses.
- Baseline characteristics differed between the 400 mg and 600 mg post-abiraterone cohorts: median age 67 and 77 years, prior docetaxel 39% and 13%, and median baseline PSA 26 and 12 ng/mL. The exposure-response analysis used to select the RP3D pooled 113 participants from single-agent and combination cohorts.
- All results are company-reported in press releases, investor presentations, and SEC filings. ORIC states that outcomes “may materially change as patient enrollment continues or more patient data become available”, that it may report unconfirmed responses and “interim analyses of only certain endpoints rather than all endpoints”, and that early clinical results “may not be predictive” of later-stage trials. ORIC’s comparisons with mevrometostat use competitor rPFS percentages “estimated from published data” and are labeled cross-trial.